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Abstract
Background: Re-biopsy for resistant non-small cell lung cancer (NSCLC) after treatment with epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is important for selection of better therapy, but there have
been no reports about the utility of endobronchial ultrasound (EBUS)-guided procedures for such purpose. The aim
of this study was to evaluate the utility of EBUS-guided re-biopsy for resistant NSCLC after treatment with
EGFR-TKIs.
Methods: From January 2013 to December 2015, 53 consecutive patients who underwent EBUS-guided re-biopsy
for mutation analysis of NSCLC after EGFR-TKI treatment were assessed.
Results: Nine patients underwent EBUS-guided transbronchial needle aspiration (EBUS-TBNA) and 44 patients
underwent EBUS with a guide sheath (EBUS-GS) transbronchial biopsy. The technical success rates were 100 %. As
for mutation analysis, all 9 specimens (100 %) from EBUS-TBNA and 33 specimens (75.0 %) from EBUS-GS were
adequate for gene profiling. The remaining 11 specimens from EBUS-GS procedures were inadequate for mutation
analysis owing to the absence of tumor component in the sample (n = 6) or insufficient specimen (n = 5). There
were no related severe complications.
Conclusions: Re-biopsy by both EBUS-TBNA and EBUS-GS were useful and safe sampling procedures for mutation
analysis of EGFR-TKI resistant NSCLC.
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Background
Epidermal growth factor receptor tyrosine kinase inhibi-
tors (EGFR-TKIs) have been demonstrated to be effect-
ive in treating non-small cell lung cancer (NSCLC)
patients with EGFR mutations [1–3]. EGFR-TKIs offer
both good clinical response and survival benefit in
NSCLC patients who have EGFR mutation [4]. However,
a majority of the responders eventually develop acquired
resistance to EGFR-TKIs [5].
Until now, several studies have uncovered several
mechanisms of acquired resistance, such as secondary
EGFR mutations (T790M mutation), mesenchymal-to-
epithelial transition factor receptor (MET) amplification,
and human epidermal growth factor receptor 2 (HER2)
gene amplification [6]. Among these, a secondary mis-
sense T790M mutation was observed in nearly half of all
cases that were resistant to EGFR-TKIs [7].
In November 2015, a third generation EGFR-TKI
(Osimertinib; Astra Zeneca, London) has been approved
by the US Food and Drug Administration (FDA) to treat
patients with a type of advanced NSCLC that has a spe-
cific EGFR mutation, called T790M, and which has be-
come worse after treatment with other EGFR-TKIs.
Osimertinib has shown clinical effectiveness and toler-
ability in NSCLC patients with T790M mutation of
EGFR [8].* Correspondence: drtake1118@gmail.com
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Examining T790M is very important in treatment se-
lection. Because EGFR-TKI treatment is indicated for
advanced and unresectable NSCLC, examination for
T790M mutation is usually performed on small biopsy
specimens.
So far, most reports on re-biopsy procedures after EGFR-
TKI resistance have been on computed tomography-
guided transthoracic needle biopsy (CTNB), which is also
the common first method of choice for the initial diagnosis
of lung cancer [9]. However, complications, such as
pneumothorax and bleeding, after CTNB have been re-
ported [9].
Another biopsy approach is by bronchoscopy, but its
use has been limited by a lower diagnostic accuracy
compared with CTNB. Recently, endobronchial ultra-
sound (EBUS) guidance during bronchoscopy proce-
dures, such as EBUS guided-transbronchial needle
aspiration (EBUS-TBNA) and EBUS with a guide sheath
(EBUS-GS) transbronchial biopsy, have been introduced
and improved the diagnostic accuracy of bronchoscopy
[10, 11]. However, there have been no reports about the
utility of EBUS procedures for re-biopsy.
In this study, we evaluated the efficacy and safety of




This study was approved by the National Cancer Center
Institutional Review Board. Written informed consent
for the procedure was obtained from all patients. Con-
secutive patients who underwent re-biopsy by EBUS
procedures for mutation analysis of NSCLC after EGFR-
TKI treatment at the hospital between January 2013 and
December 2015 were enrolled. There were 2907 patients
in whom EBUS-guided bronchoscopy procedures were
performed during the study period. Among these, 89
patients were for re-biopsy purposes. Among these re-
biopsy patients, we selected NSCLC patients who were
treated with at least one EGFR-TKI regimen. Disease
progression during chemotherapy, based on the RECIST
ver1.1 definition, was a criterion for inclusion; 36
patients were ineligible because of the absence of prior
EGFR-TKI treatment.
Methods and equipment
All bronchoscopies were performed via the oral route
under local anesthesia with mild sedation by intravenous
administration of midazolam.
EBUS-GS was performed for patients with peripheral
pulmonary lesions (PPLs) without mediastinal and hilar
lymphadenopathy; a GS kit (K-201 or K-203; Olympus
Ltd, Tokyo, Japan) and a radial EBUS (R-EBUS) probe
(UM-S20-20R or UM-S20-17S; Olympus Ltd, Tokyo,
Japan) were used. The bronchial route was planned by
reviewing the chest CT images before EBUS-GS. Virtual
bronchoscopic navigation/simulation systems (Ziostation2,
Ziosoft Ltd, Tokyo, Japan; LungPoint, Bronchus Ltd,
Mountain View, CA, USA; or Bf-Navi, Olympus Ltd,
Tokyo, Japan) were used to detect the bronchial route to
the target PPLs. A PPL was defined as an abnormal
growth surrounded by normal lung parenchyma and was
bronchoscopically invisible. Upon reaching the target
bronchus, the GS together with the R-EBUS probe was
inserted through the working channel of the bronchovi-
deoscope and was advanced towards the PPL under
fluoroscopic guidance (VersiFlex VISTAVR; Hitachi Ltd,
Tokyo, Japan). Ultrasound scanning was performed while
manipulating the R-EBUS probe until the lesion was local-
ized by the corresponding EBUS image. After confirming
the location of the PPLs, the R-EBUS probe was removed
while keeping the GS in place for the usual transbronchial
sampling using forceps, brush, and/or transbronchial nee-
dle aspiration under fluoroscopic guidance. Lesion loca-
tion was assigned based on a study of Baaklini et al. [12],
but with some modifications. With the area around the
hilum on CT as reference, lesions in the inner and middle
third ellipses were designated as central parenchymal loca-
tion, whereas lesions in the outer third ellipse were desig-
nated as peripheral parenchymal location. The bronchus
sign on CT was defined as the presence of a bronchus
leading directly to a PPL [13].
EBUS-TBNA was performed for patients who had me-
diastinal and hilar lymphadenopathy. EBUS–TBNA was
performed using either one of the following 22G needles:
Vizishot (NA-201SX-4022; Olympus Ltd, Tokyo, Japan)
or SonoTip EBUS Pro with stainless steel (GUS-45-18-
022; Medi-Globe Ltd, Germany). The convex probe
EBUS (CP-EBUS; BF-UC260FW, Olympus Ltd, Tokyo,
Japan) was inserted through the oral route in the same
way as during usual bronchoscopy. The ultrasound
images were generated using a dedicated ultrasound
processor (EU-ME1 or EU-ME2; Olympus Ltd, Tokyo,
Japan). When the target lesions were visualized by CP-
EBUS, the TBNA needle was inserted through the work-
ing channel of the bronchoscope and was advanced to
penetrate the tracheobronchial wall into the target lesion
under real-time EBUS guidance. Aspiration was done by
moving the needle back and forth inside the target lesion
for 20–30 times, under negative pressure. After sam-
pling, suction was released before retracting the needle
from the scope.
Pathologic evaluation and mutation analysis
Cytology and histology specimens were sent for patho-
logic examination. Positive diagnostic criteria suitable
for molecular analysis were defined by the presence of
malignant cells based on histologic features or based on
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class IV/V on cytology examination by Papanicolaou
stain. Overall detection rate was based on a positive
diagnosis by histology and/or cytology.
EGFR mutation analyses of the genomic DNA extracted
from tumor samples were performed using the Scorpion
ARMS method.
Statistical analysis
Descriptive statistics were presented as frequency, per-
centage, and median (range). Univariate analyses were
performed using Fisher’s exact test. Multivariate analysis
using logistic regression was performed to determine the
factors associated with the yield. Variables selected via
univariate analyses (P value <0.10) were evaluated using
multivariate logistic regression analysis. A two-tailed P
value <0.05 was considered to indicate statistical signifi-
cance. Correlation of study variables were performed
with EZR (Saitama Medical Center, Jichi Medical
University; www.jichi.ac.jp/saitama-sct/SaitamaHP.files/
statmed.html), a graphical user interface for R (version
2.13.0, The R Project for Statistical Computing; http://
www.r-project.org) and a modified version of R commander
(version 1.8-4).
Results
After exclusion, a total of 53 patients were included in
this study population. In the 53 patients, the original
diagnoses were established by CTNB in 2 cases; by
EBUS-TBNA in 5 cases; by EBUS-GS in 39 cases; and by
surgical biopsy in 7 cases. There were no cases with
positive T790M mutation upon initial diagnosis.
For re-biopsy, EBUS–TBNA was performed in 9 pa-
tients, whereas EBUS-GS was performed in 44 patients.
The technical success rates of the re-biopsy procedures
were 100 %. All 9 specimens (100 %) from EBUS-TBNA
and 33 specimens (75.0 %) from EBUS-GS were ad-
equate for gene profiling and mutation analysis. The
remaining 11 specimens from EBUS-GS procedures
were inadequate for mutation analysis owing to the
absence of tumor component in the sample (n = 6) or
insufficient specimen (n = 5).
The baseline characteristics of the study population
are summarized in Table 1. Initially, EGFR mutation was
detected in 53 cases (exon 19 deletion in 30, L858R
point mutation in 22, and L861Q point mutation in 1).
Among 42 patients that had adequate samples for
gene profiling testing for EGFR mutation, 22 (52.4 %)
had EGFR mutation and T790M-resistant mutation
(Table 2). One initial EGFR-mutated tissue revealed
SCLC transformation.
The adequacy of the re-biopsy specimens for mutation
analysis is described in Table 3. The overall detection
rate of re-biopsy for malignant cells was 79.2 % (42 of
53); 77.4 % (41 of 53) by cytology and 77.4 % (41 of 53)
by histologic examination. The detection rate of re-biopsy
by EBUS-TBNA for malignant cells was 100 % (9 of 9),
100 % (9 of 9) by cytology and 88.9 % (8 of 9) by histologic
examination. In contrary, the detection rate of re-biopsy
by EBUS-GS for malignant cells was 75.0 % (33 of 44);
Table 1 Patient demographics and clinical information (N = 53)
Characteristics












Adenosquamous cell carcinoma 1 (1.9)








Gefitinib + Erlotinib 12 (22.6)
Gefitinib + Afatinib 1 (1.9)
Gefitinib + Erlotinib + Afatinib 4 (7.5)
Data are presented as median (range) or number (%)
ECOG PS Eastern Cooperative Group performance status, EGFR epidermal
growth factor receptor, EGFR-TKI EGFR-tyrosine kinase inhibitor
Table 2 Biological profiles of cases that underwent re-biopsy by
EBUS procedures (N = 53)
Initial EGFR mutation profile EGFR mutation profile on
re-biopsy
Del19 30 Del19 alone 8
Del19 + T790M 16
Re-biopsy failure 6
L858R 22 L858R alone 11
L858R + T790M 6
Re-biopsy failure 5
L816Q 1 L816Q alone 1
Data are presented as number
EBUS endobronchial ultrasound, EGFR epidermal growth factor receptor
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72.7 % (32 of 44) by cytology and 75.0 % (33 of 44) by
histologic examination (Table 3).
The factors affecting re-biopsy by EBUS-GS are shown
in Table 4. In the multivariate analysis, central parenchy-
mal location and EBUS probe within were the significant
predictors of a successful EBUS-GS re-biopsy.
There were no severe complications after both EBUS-
TBNA and EBUS-GS re-biopsy procedures.
Discussion
Currently, the significance of re-biopsy for mutation
analysis of NSCLC has been increasing because of a
wider range of therapeutic options. The standard cyto-
toxic chemotherapy for NSCLC patients has limited
therapeutic response [14]. Moreover, after treatment
with EGFR-TKIs, kinase inhibition frequently leads to
the appearance of drug-resistant mutations within the
target kinase itself [15, 16]. Recently, a third generation
EGFR-TKI (Osimertinib) has been approved by the US
FDA to treat patients with a type of advanced NSCLC
that has a specific EGFR mutation, called T790M, and
which has become worse after treatment with other
EGFR-TKIs. Moreover, Osimertinib has shown clinical
effectiveness and tolerability in NSCLC patients with
T790M mutation of EGFR [8], underscoring the import-
ance of checking for new mutations after EGFR-TKI
therapy in advanced NSCLC patients. There have been
several reports about the utility of re-biopsy by CTNB
for such purpose.
To our best knowledge, this study was the first to
demonstrate the utility of bronchoscopic procedures, es-
pecially with EBUS guidance, for mutation analysis of
NSCLC after EGFR-TKI therapy. EBUS is a very import-
ant procedure to determine and collect samples from
target sites in the mediastinal, hilar, and peripheral loca-
tions under real-time ultrasound [17, 18]. Adequate
sampling of histologic specimens is necessary for the de-
velopment of new treatment options for cancer, especially
chemotherapy and gene-targeted therapy; therefore,
further improvements of the histologic sampling yield
is essential [19, 20].
EBUS-TBNA is an established minimally invasive pro-
cedure for proper staging and diagnosis of lung cancer
[10, 21]. In this study, EBUS-TBNA was performed suc-
cessfully and was able to obtain adequate samples in all
cases. EBUS-TBNA is useful not only for proper staging
and diagnosis of lung cancer, but also to obtain samples
for mutation analysis of NSCLC after EGFR-TKI, as
demonstrated in this study. Furthermore, EBUS-TBNA
was a safe re-biopsy procedure and had no associated
severe complications.
In this study, EBUS-GS was able to obtain samples for
mutation analysis of NSCLC after EGFR-TKI. However,
when compared with EBUS-TBNA, the detection rate
Table 3 Adequacy of re-biopsy samples for molecular analysis
(N = 53)
Detection rate of re-biopsy for malignant cells
Cytology Histology Overall
ALL 53 41 (77.4) 41 (77.4) 42 (79.2)
EBUS-TBNA 9 9 (100) 8 (88.9) 9 (100)
EBUS-GS 44 32 (72.7) 33 (75.0) 33 (75.0)
Data are presented as number (%)
EBUS-TBNA endobronchial ultrasound-guided transbronchial needle aspiration,
EBUS-GS endobronchial ultrasound with a guide sheath







p value p value Odds
ratio
Age (years) 0.722 – –
≤70 23 (52.3) 7 (15.9)
>70 10 (22.7) 4 (9.1)
Gender 0.282 – –
Male 13 (29.5) 2 (4.5)
Female 20 (45.5) 9 (20.5)
ECOG PS 1.0 – –
0/1 31 (70.5) 10 (22.7)
2/3/4 2 (4.5) 1 (2.3)
Size (mm) 0.139 – –
≤30 7 (15.9) 5 (11.4)
>30 26 (59.1) 6 (13.6)
Location 0.043 0.034 15.7
Central
parenchymal
32 (72.7) 8 (18.2)
Peripheral
parenchymal
1 (2.3) 3 (6.8)
Bronchus sign 0.027 0.239 –
Positive 31 (70.5) 7 (15.9)




Primary malignant 30 (68.2) 8 (18.2)
Metastatic 3 (6.8) 3 (6.8)
Chest radiograph 0.090 0.080 –
Visible 31 (70.5) 8 (18.2)
Invisible 2 (4.5) 3 (6.8)
EBUS 0.016 0.012 10.0
Within 30 (68.2) 6 (13.6)
Adjacent
to/invisible
3 (6.8) 5 (11.4)
Data are presented as number (%)
EBUS-GS endobronchial ultrasound with a guide sheath, ECOG PS Eastern
Cooperative Group performance status, EBUS Endobronchial ultrasound
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for malignancy was only 75 %. The yield of EBUS-GS for
primary diagnosis of PPLs has been reported to be about
70–80 % [22], which is similar to the yield for re-biopsy
for mutation analysis in this study. The factors that in-
fluence the diagnostic yield of EBUS-GS for PPLs have
been reported to be the location of the PPL (central par-
enchymal or peripheral parenchymal), detected EBUS
images (within or adjacent to/invisible), and the presence
of a bronchus sign. Although central parenchymal loca-
tion and detection of EBUS image within were significant
factors that predicted a successful yield, the number of
peripheral parenchymal cases in this study was small. Fur-
ther study is needed to confirm the usefulness of EBUS-
GS according to the location of the lesion. Although there
is need for further technical improvement, EBUS-GS was
useful to get samples for mutation analysis of NSCLC
after EGFR TKI treatment. In addition, EBUS-GS had no
severe complications.
CTNB is another diagnostic procedure for PPLs, with
a relatively high rate of both diagnostic accuracy and
complications, such as pneumothorax. On the contrary,
EBUS-GS was a safe method [23]. However, it is import-
ant to note that although EBUS-GS might be considered
one of the sampling procedures to safely obtain tissues
from PPLs for mutation analysis of NSCLC after EGFR-
TKI treatment, the detection rate for malignant cells
was significantly lower for peripherally located lesions,
as shown in this study. In this regard, EBUS-GS should
be performed to get samples for mutation analysis of le-
sions that are in a central parenchymal location.
Another alternative approach, specifically liquid bi-
opsy, now present as a crucial point in the field [24].
Liquid biopsy has grown in importance because the gen-
etic profile of tumors can affect how well they respond
to a certain treatment. A recent paper showed that the
concordance between re-biopsy and liquid biopsy, in-
cluding plasma DNA and circulating tumor cell, was
57–60 % [25]. The usefulness of monitoring T790M sta-
tus in liquid biopsy was already reported [26]. Although
liquid biopsy has the potential to detect new mutations
after chemotherapy, several reports have demonstrated
some difficulties in detecting tumor-derived mutations
in plasma [27]. Therefore, liquid biopsy and re-biopsy
may be considered to be complementary methods of
mutation analysis.
The limitations of this study were its retrospective and
single-institution design. Prospective, multi-center trials
are ideal and recommended in the future.
Conclusions
EBUS procedures for re-biopsy were useful sampling
methods for mutation analysis of NSCLC after EGFR-
TKI treatment. This could play an important role in
the choice of better targeted therapy and for the
development of a novel treatment for advanced lung
cancer patients.
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